0.00
price down icon100.00%   -15.96
 
loading
Schlusskurs vom Vortag:
$15.96
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$22.12M
Einnahmen:
$20.97M
Nettoeinkommen (Verlust:
$-118.51M
KGV:
0.00
EPS:
-2.19
Netto-Cashflow:
$-94.45M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$19.08

Cara Therapeutics Inc Stock (CARA) Company Profile

Name
Firmenname
Cara Therapeutics Inc
Name
Telefon
203-406-3700
Name
Adresse
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Name
Mitarbeiter
55
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
CARA's Discussions on Twitter

Vergleichen Sie CARA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CARA
Cara Therapeutics Inc
0.00 22.12M 20.97M -118.51M -94.45M -2.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
375.63 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
559.80 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
435.10 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
672.35 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
298.29 35.49B 3.81B -644.79M -669.77M -6.24

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-14 Eingeleitet Raymond James Outperform
2025-07-11 Eingeleitet Cantor Fitzgerald Overweight
2025-06-12 Eingeleitet Piper Sandler Overweight
2025-05-21 Eingeleitet Oppenheimer Outperform
2025-05-15 Eingeleitet BTIG Research Buy
2024-06-13 Herabstufung Canaccord Genuity Buy → Hold
2024-06-13 Herabstufung H.C. Wainwright Buy → Neutral
2024-06-13 Herabstufung Needham Buy → Hold
2024-06-13 Herabstufung Stifel Buy → Hold
2023-03-08 Herabstufung BofA Securities Neutral → Underperform
2022-03-08 Hochstufung JP Morgan Neutral → Overweight
2021-11-01 Fortgesetzt Canaccord Genuity Buy
2021-08-03 Eingeleitet JP Morgan Neutral
2020-04-21 Bestätigt H.C. Wainwright Buy
2019-08-12 Bestätigt H.C. Wainwright Buy
2019-05-29 Bestätigt Laidlaw Buy
2019-02-06 Fortgesetzt Jefferies Buy
2019-01-15 Eingeleitet BofA/Merrill Neutral
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2018-09-13 Eingeleitet Jefferies Buy
2018-08-08 Bestätigt Stifel Buy
2018-06-28 Bestätigt H.C. Wainwright Buy
2018-03-12 Fortgesetzt H.C. Wainwright Buy
2018-02-12 Hochstufung Janney Neutral → Buy
2018-01-19 Eingeleitet Seaport Global Securities Buy
2017-06-30 Herabstufung Janney Buy → Neutral
2017-06-30 Bestätigt Laidlaw Buy
2017-06-30 Bestätigt Stifel Buy
2017-03-28 Bestätigt H.C. Wainwright Buy
2017-03-28 Bestätigt Laidlaw Buy
2017-03-10 Bestätigt Laidlaw Buy
2016-10-13 Eingeleitet H.C. Wainwright Buy
2016-08-08 Bestätigt Needham Buy
Alle ansehen

Cara Therapeutics Inc Aktie (CARA) Neueste Nachrichten

pulisher
Jul 29, 2025

Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 18, 2025

This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com

Jul 18, 2025
pulisher
Jul 16, 2025

Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World

Jul 14, 2025
pulisher
Jul 13, 2025

Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jun 30, 2025

Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 13, 2025

Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 11, 2025

How To Trade (CARA) - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks

Jun 09, 2025
pulisher
May 29, 2025

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com

May 28, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks

May 27, 2025
pulisher
May 26, 2025

Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World

May 26, 2025
pulisher
May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com

May 21, 2025
pulisher
May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com

May 21, 2025
pulisher
May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India

May 21, 2025
pulisher
May 16, 2025

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World

May 16, 2025
pulisher
May 15, 2025

BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK

May 15, 2025
pulisher
May 14, 2025

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN

May 14, 2025
pulisher
May 14, 2025

Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter

May 14, 2025
pulisher
May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025
pulisher
May 08, 2025

Where are the Opportunities in (CARA) - news.stocktradersdaily.com

May 08, 2025
pulisher
May 06, 2025

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire

May 06, 2025

Finanzdaten der Cara Therapeutics Inc-Aktie (CARA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$78.20
price up icon 0.71%
$37.01
price down icon 0.30%
$109.30
price down icon 1.76%
$28.07
price down icon 1.58%
$111.35
price up icon 0.04%
biotechnology ONC
$298.29
price down icon 0.08%
Kapitalisierung:     |  Volumen (24h):